{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/d348aacb-00cd-4b2d-9b3b-ee9d99cdb735/643db1bea061c70011d45d3a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Ep 579: Ozempic on the NHS?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61ba18761a8cbe923a3cf195/1644341347732-cee380f552eeebbbc48dbc78cdd4ee15.jpeg?height=200","description":"<p>England’s NHS has approved semaglutide, Hollywood’s favourite weight-loss injection. But is the hype justified? </p><p><br></p><p>Tortoise is a newsroom devoted to slow journalism. For early access and ad-free listening subscribe to Tortoise+ on Apple Podcasts or join Tortoise for £60 a year.</p><p><br></p><p>As a member you’ll also get our newsletters and tickets to live events. Just go to&nbsp;<a href=\"http://tortoisemedia.com/slowdown\" rel=\"noopener noreferrer\" target=\"_blank\">tortoisemedia.com/slowdown</a>.</p><p><br></p><p>If you’d like to further support slow journalism and help us build a different kind of newsroom, do consider donating to Tortoise at&nbsp;<a href=\"http://tortoisemedia.com/support-us\" rel=\"noopener noreferrer\" target=\"_blank\">tortoisemedia.com/support-us</a>. Your contributions allow us to investigate, campaign and explore, and to build a newsroom that is responsible and sustainable.</p>","author_name":"The Observer"}